Embecta Stock Drops 57.8% After Disappointing Q2 Earnings Report
Embecta's stock plummeted 57.8% following the release of its Q2 fiscal 2026 earnings report, which showed significant misses in both revenue and earnings. The medical-device company reported a 14.4% year-over-year sales decline and weaker-than-expected EBITDA margins, leading to a sharp sell-off.
